Grant: EWR Steacie Fellowships - Supplement
Université de Montréal
$130,700.00
Steacie Supplement
FY 2008-09
Summary
There is increasing optimism with respect to nanotechnology giving rise to significant advances in the fields of cancer diagnosis and treatment. In recent years, the use of water-soluble polymers as nanocarriers of cytotoxic drugs has attracted wide interest. It is now well-established that long-circulating drug-polymer conjugates accumulate in a variety of solid tumors at much higher concentrations than in normal tissues. Due to their limited distribution in healthy tissues, they often display safer toxicological profiles than control drug solutions. However, despite these attractive characteristics, polymeric conjugates are seldom associated with a greater antitumoral activity than the free drug at equivalent doses. This can often be rationalized in terms of insufficient intracellular concentrations of bioavailable drug due to a slow release rate of the active agent in the tumor cells. Indeed, for optimal cytostatic activity, the drug should be rapidly released from the carrier upon reaching the malignant cells. To achieve this objective, we propose to construct polymer conjugates whereby the drug is released as a result of the conformational change of a nanomechanical device (i.e. molecular tweezer) grafted to the polymeric backbone. Molecular tweezers can be designed to express very high affinity for a substrate when in a specific conformation, and then rapidly lose their binding properties following a change in their molecular shape. This conformational change can be triggered by acidification of the external medium, a condition that is encountered by macromolecular drugs following their uptake by the tumor cells.
Program
EWR Steacie Fellowships - Supplement
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
364039-2008
Name nom
Leroux, JeanChristophe
Department département
Pharmacie, faculté de
Organization id
63
Institution établissement
Université de Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2008
Competition year année de concours
2008
Award amount
130700
Program id
SMFSU
Program nane en
EWR Steacie Fellowships - Supplement
Program name fr
EWR Steacie - Supplément
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
104
Committee name en
Steacie Fellowship Sel Cttee
Committee name fr
Cté de sél des bourses Steacie
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1902
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical materials
Research subject fr
Matériaux biomédicaux
Partie
1
Nb partie
2
Application title
Steacie Supplement
Keyword
NA
Application summary
There is increasing optimism with respect to nanotechnology giving rise to significant advances in the fields of cancer diagnosis and treatment. In recent years, the use of water-soluble polymers as nanocarriers of cytotoxic drugs has attracted wide interest. It is now well-established that long-circulating drug-polymer conjugates accumulate in a variety of solid tumors at much higher concentrations than in normal tissues. Due to their limited distribution in healthy tissues, they often display safer toxicological profiles than control drug solutions. However, despite these attractive characteristics, polymeric conjugates are seldom associated with a greater antitumoral activity than the free drug at equivalent doses. This can often be rationalized in terms of insufficient intracellular concentrations of bioavailable drug due to a slow release rate of the active agent in the tumor cells. Indeed, for optimal cytostatic activity, the drug should be rapidly released from the carrier upon reaching the malignant cells. To achieve this objective, we propose to construct polymer conjugates whereby the drug is released as a result of the conformational change of a nanomechanical device (i.e. molecular tweezer) grafted to the polymeric backbone. Molecular tweezers can be designed to express very high affinity for a substrate when in a specific conformation, and then rapidly lose their binding properties following a change in their molecular shape. This conformational change can be triggered by acidification of the external medium, a condition that is encountered by macromolecular drugs following their uptake by the tumor cells.